1. Effect of pioglitazone on biochemical indices of non-alcoholic fatty liver disease in upper body obesity 
Samyah Shadid, Michael D Jensen 
Clinical Gastroenterology and Hepatology 
Volume 1, Issue 5, Pages (September 2003)
DOI: /S (03)

2. Figure 1
The mean and SD of the AST and ALT over time during pioglitazone treatment are depicted. The difference between the effect of pioglitazone on AST (P = 0.05) and ALT (P < ) was significant between NAFLD and previously normal liver function tests. The dashed line represents the top of the normal range.
Clinical Gastroenterology and Hepatology 2003 1, DOI: ( /S (03) )